Germany-based Stratec Biomedical has an option to acquire up to 7% of US-based healthcare testing peer Quanterix as part of a partnership. The two companies said they would co–develop and manufacture a fully–automated instrument for Quanterix’s SiMoA technology (pictured) for use in both the life sciences and in vitro diagnostics (IVD) markets. As part of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
